Recent Company News

• 05:02 PM ET Nov 12, 2025
  

  Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance (CHF 104.70, 0.00)

• 01:16 AM ET Nov 04, 2025
  

  Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston (CHF 99.50, 0.00)

• 05:30 PM ET Oct 31, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 08:54 AM ET Oct 31, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 12:34 AM ET Oct 31, 2025
  

  Novartis upgraded to overweight from equal-weight at Morgan Stanley (CHF 98.88, 0.00)

• 04:26 PM ET Oct 30, 2025
  

  Transcript Intelligence: Novartis Business Update Call (CHF98.88, 0.00)

• 04:17 PM ET Oct 29, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:12 PM ET Oct 29, 2025
  

  HHS issues press release on accelerating biosimilar drug development and lowering drug prices

• 10:37 AM ET Oct 29, 2025
  

  Novartis ianalumab reduces disease activity and patient burden in Sjögren's disease Phase III trials (CHF 97.76, -1.11)

• 09:21 AM ET Oct 29, 2025
  

  FDA announces draft guidance for biosimilar development